Skip to main content
. 2021 Apr 5;23(11):1872–1884. doi: 10.1093/neuonc/noab081

Table 2.

Univariate and Multivariate Analyses of Survival After Transformation

Survival After Transformation, Grade III Tumors Only
Univariate Multivariate
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Subtype
IDH-mutant 1p/19q co-deleted oligodendroglioma 1 Reference - 1 Reference -
IDH-mutant astrocytoma 1.27 0.55-2.95 0.58 2.56 0.84-7.76 0.098
Hypermutation
 Non-HM 1 Reference - 1 Reference -
 HM 2.32 1.00-5.40 0.051 3.42 1.18-9.92 0.024
Prior RT
 No prior RT 1 Reference - 1 - Reference
 Prior RT 2.8 1.20-6.54 0.018 3.33 1.36-8.13 0.0084
Age at transformation (per year increase) 1.03 0.99-1.08 0.16 1.03 0.98-1.10 0.34
Time to transformation (per year increase) 0.963 0.86-1.08 0.51
KPSa 0.95 0.92-0.99 0.024
Extent of resection
 STR or biopsy 1 Reference -
 GTR 1.05 0.24-4.52 0.95
CDKN2A status
 No homozygous deletion 1 Reference -
 Homozygous deletion 1.65 0.38-7.10 0.51
Survival After Transformation, All Transformed Tumors
Univariate
Hazard Ratio 95% CI P Value
Subtype
IDH-mutant 1p/19q co-deleted oligodendroglioma 1 Reference -
IDH-mutant astrocytoma 2.45 1.23-4.86 .011
Hypermutation
 Non-HM 1 Reference -
 HM 2.15 1.14-4.04 .018
Grade III vs IV
 Grade III 1 Reference -
 Grade IV 6.05 2.92-12.52 <.0001
Prior RT
 No prior RT 1 Reference -
 Prior RT 1.83 0.97-3.43 .061
Age at transformation (per year increase) 1.03 0.70-1.34 .85
Time to transformation (per year increase) 0.95 0.87-1.03 .21
KPSa 0.96 0.93-0.99 .017
Extent of resection
 STR or biopsy 1 Reference -
 GTR 0.75 0.23-2.46 .64
CDKN2A status
 No homozygous deletion 1 Reference -
 Homozygous deletion 0.72 0.42-4.51 .59

Abbreviations: GTR, gross total resection of enhancing and non-enhancing disease; HM, hypermutated; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; RT, radiation therapy; STR, subtotal resection of enhancing and non-enhancing disease.

aKPS not included in multivariable models because of missing data (n = 33).